Samsara Therapeutics is focused on developing innovative therapies for neurodegenerative diseases by harnessing the power of autophagy activation. Their mission is to delay the progression of conditions such as Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD), and Charcot-Marie-Tooth Disease (CMT) through a range of targeted programs. The company has established a robust pipeline that includes specific programs like SAM001 for ALS, which aims to leverage lysosomal biogenesis, and SAM0021 and SAM0022 for PD and CMT, respectively, focusing on autophagosome formation. Additionally, SAM005 targets phagophore recruitment for CMT, showcasing a comprehensive approach to addressing various neurodegenerative indications.

Central to Samsara's drug discovery efforts is their in-house phenotypic screening platform, which utilizes patient-derived induced pluripotent stem cells (iPSCs) to identify and validate potential autophagy activators. This platform allows for high-throughput, cell-based screening that is tailored to disease-relevant contexts, enabling the efficient progression of promising compounds through preclinical and clinical development stages. By integrating advanced screening techniques with a focus on autophagy, Samsara Therapeutics aims to provide new therapeutic options for patients and their families affected by age-related neurodegenerative diseases.

United States

Samsara Therapeutics, Inc. is biopharmaceutical company aiming to discover first-in-class therapeutics that treat rare genetic and neurodegenerative disease, and extend healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy. Samsara Therapeutics is a global biotech company with operations in Oxford and Boston and significant academic collaborations in Paris and Graz

Samsara Therapeutics

Company Details